ArticleBritish journal of cancer2023

An antibody-drug conjugate targeting GPR56 demonstrates efficacy in preclinical models of colorectal cancer.

Joan Jacob et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.